Please login to the form below

Not currently logged in
Email:
Password:

Pfizer appoints diabetes expert Morris Birnbaum

He takes up post as chief scientific officer for cardiovascular and metabolic diseases

Morris Birnbaum PfizerPfizer has appointed prominent academic Dr Morris Birnbaum as chief scientific officer for its research into cardiovascular and metabolic diseases.

Dr Birnbaum most recently served as Willard Ware professor of diabetes and metabolic diseases and associate dean for biomedical core resources at the Perelman School of Medicine at the University of Pennsylvania.

In his academic career he has authored more than 200 scientific papers and has built an expertise in intracellular metabolism - a key component to understanding diabetes and its relationship to cardiovascular disease.

“His scientific credentials and knowledge will help Pfizer pursue our goals to achieve industry leadership from the strong position that we currently hold, and to deliver unique therapies for patients,” said Dr Rod MacKenzie, group senior VP and head of PharmaTherapeutics R&D.

Pfizer's interests in the area include a collaboration with Merck & Co on the sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin to treat diabetes. The company is also developing bococizumab for hypercholesterolemia.

5th June 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics